Risk of stroke following discontinuation of oral anticoagulant treatment for atrial fibrillation: a cohort study

Date of Approval
Application Number
16_132
Technical Summary

Objectives
The objective is to estimate the risk of stroke in patients with atrial fibrillation (AF) who are initially treated with vitamin K antagonists (VKAs), comparing patients discontinuing VKAs with those currently using VKAs.
Methods
This will be a population-based cohort study in patients treated with VKAs for AF, analysed using a nested case-control approach. The cohort of patients with an incident AF treated with VKAs will be identified from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). For each patient with a stroke during the observational period (cases), controls without a stroke will be selected from the VKA-treated AF cohort. Strokes will be identified from CPRD, HES and Office of National Statistics (ONS) mortality data.
Data analysis
The relative risk of VKA discontinuation compared to VKA continuation with regard to stroke will be estimated from crude and adjusted odds ratios (ORs) derived from conditional logistic regression for matched case–control data using current VKA use as the reference category.

Health Outcomes to be Measured

Incident strokes occurring during the study period after AF diagnosis

Collaborators

Carlos Martinez - Chief Investigator - Institute for Epidemiology, Statistics and Informatics GmbH (Pharma Epi)
Ben Freedman - Collaborator - ANZAC Research Institute
Christopher Wallenhorst - Collaborator - Institute for Epidemiology, Statistics and Informatics GmbH (Pharma Epi)

Linkages

HES Admitted Patient Care;HES Outpatient;ONS Death Registration Data;Patient Level Index of Multiple Deprivation;Practice Level Index of Multiple Deprivation